Circulating levels of osteopontin, osteoprotegerin, total soluble receptor activator of nuclear factor‐kappa B ligand, and high‐sensitivity C‐reactive protein in patients with active rheumatoid arthritis randomized to etanercept alone or in combination with methotrexate
Authors:
- H. P. SennelsHSH. P. Sennels
- S. SørensenSSS. Sørensen
- M. ØstergaardMØM. Østergaard
- L. S. KnudsenLKL. S. Knudsen
- M. S. HansenMHM. S. Hansen
- H. SkjødtHSH. Skjødt
- N. D. PetersNPN. D. Peters
- A. ColicACA. Colic
- K. GrauKGK. Grau
- S. JacobsenSJS. Jacobsen
- 1 January 2008
- journal article
- research article
- Published by Taylor & Francis in Scandinavian Journal of Rheumatology
- Vol. 37 (4) , 241-247
Abstract
To determine whether circulating levels of osteopontin (OPN), osteoprotegerin (OPG), total soluble receptor activator of nuclear factor-kappa B ligand (total sRANKL), and high-sensitivity C-reactive protein (hsCRP) change in patients with rheumatoid arthritis (RA) during immunosuppressive therapy. Twenty-five active RA patients were randomized to treatment with either etanercept alone or in combination with methotrexate (MTX). The treatment response after 16 weeks was assessed using the European League Against Rheumatism (EULAR) response criteria. Blood samples were taken before the start of and every fourth week during the study. OPN, OPG, and total sRANKL were measured by enzyme-linked immunosorbent assays (ELISAs) and hsCRP by highly sensitive turbidometry. At baseline, OPN and hsCRP were significantly (p<0.001) elevated compared to healthy persons. Compared to baseline only hsCRP levels decreased significantly (p<0.05 to p<0.001) in the EULAR responders through the study. OPN remained significantly (p<0.05) elevated at 16 weeks in patients with a low disease activity score (DAS< or =3.2). Total sRANKL increased significantly (p<0.05) from baseline to week 12. No statistically significant changes were observed in the non-responders. Active RA patients showed increased circulating levels of hsCRP and OPN, but only hsCRP decreased during etanercept therapy. Our findings suggest that OPN, OPG, total sRANKL, and hsCRP reflect different aspects of the inflammatory process in RA.Keywords
This publication has 25 references indexed in Scilit:
- Baseline serum RANKL levels may serve to predict remission in rheumatoid arthritis patients treated with TNF antagonistsAnnals of the Rheumatic Diseases, 2007
- No erosive progression revealed by MRI in rheumatoid arthritis patients treated with etanercept, even in patients with persistent MRI and clinical signs of joint inflammationClinical Rheumatology, 2007
- Biological variation and reference intervals for circulating osteopontin, osteoprotegerin, total soluble receptor activator of nuclear factor kappa B ligand and high‐sensitivity C‐reactive proteinScandinavian Journal of Clinical and Laboratory Investigation, 2007
- Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFκB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritisAnnals of the Rheumatic Diseases, 2006
- The effect of methotrexate (MTX) on expression of signalling lymphocytic activation molecule (SLAM) in patients with rheumatoid arthritis (RA) and its role in the regulation of cytokine productionScandinavian Journal of Rheumatology, 2006
- Twenty eight joint count disease activity score in recent onset rheumatoid arthritis using C reactive protein instead of erythrocyte sedimentation rateAnnals of the Rheumatic Diseases, 2003
- High levels of osteoprotegerin and soluble receptor activator of nuclear factor κB ligand in serum of rheumatoid arthritis patients and their normalization after anti–tumor necrosis factor α treatmentArthritis & Rheumatism, 2002
- Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two‐year radiographic and clinical outcomesArthritis & Rheumatism, 2002
- Elevated levels of osteoprotegerin (OPG) and hepatocyte growth factor (HGF) in rheumatoid arthritisScandinavian Journal of Rheumatology, 2001
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988